La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Relmada Therapeutics Crescita futura
Future criteri di controllo 0/6
Si prevede che Relmada Therapeutics aumenterà gli utili e i ricavi rispettivamente del 12.5% e 67.4% all'anno, mentre si prevede che l'EPS crescerà del 28.9% all'anno.
Informazioni chiave
12.5%
Tasso di crescita degli utili
28.9%
Tasso di crescita dell'EPS
| Pharmaceuticals crescita degli utili | 23.6% |
| Tasso di crescita dei ricavi | 67.4% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 08 Aug 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Mar 21Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 13
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Jan 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Dec 04Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Aug 29We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
May 07We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Dec 15Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Oct 14Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Sep 14Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Aug 09We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Jul 14Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Feb 264 Clinical Catalysts On Tap For Relmada In 2022
Jan 28Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
Nov 04Our First Look At Relmada Therapeutics
Jun 28We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Jun 28Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Mar 09What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
Jan 15
Enrollment underway in Relmada Therapeutics' late-stage depression study with REL-1017
Dec 07Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Dec 02Relmada Therapeutics (RLMD) Investor Presentation - Slideshow
Nov 16Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 48 | -114 | N/A | N/A | 4 |
| 12/31/2025 | N/A | -100 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -82 | N/A | N/A | 4 |
| 6/30/2024 | N/A | -87 | -48 | -48 | N/A |
| 3/31/2024 | N/A | -94 | -48 | -48 | N/A |
| 12/31/2023 | N/A | -99 | -52 | -52 | N/A |
| 9/30/2023 | N/A | -112 | -77 | -77 | N/A |
| 6/30/2023 | N/A | -129 | -93 | -93 | N/A |
| 3/31/2023 | N/A | -144 | -101 | -101 | N/A |
| 12/31/2022 | N/A | -157 | -104 | -104 | N/A |
| 9/30/2022 | N/A | -153 | -106 | -106 | N/A |
| 6/30/2022 | N/A | -157 | -100 | -100 | N/A |
| 3/31/2022 | N/A | -143 | -95 | -95 | N/A |
| 12/31/2021 | N/A | -126 | -92 | -92 | N/A |
| 9/30/2021 | N/A | -112 | -61 | -61 | N/A |
| 6/30/2021 | N/A | -86 | -53 | -53 | N/A |
| 3/31/2021 | N/A | -71 | -40 | -40 | N/A |
| 12/31/2020 | N/A | -59 | -28 | -28 | N/A |
| 9/30/2020 | N/A | -43 | -25 | -25 | N/A |
| 6/30/2020 | N/A | -30 | -15 | -15 | N/A |
| 3/31/2020 | N/A | -23 | -14 | -14 | N/A |
| 12/31/2019 | N/A | -15 | -12 | -12 | N/A |
| 9/30/2019 | N/A | -18 | -11 | -11 | N/A |
| 6/30/2019 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2019 | N/A | -17 | -9 | -9 | N/A |
| 12/31/2018 | N/A | -17 | -9 | -9 | N/A |
| 9/30/2018 | N/A | -11 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -9 | -6 | -6 | N/A |
| 3/31/2018 | N/A | -7 | N/A | -5 | N/A |
| 12/31/2017 | N/A | -6 | N/A | -5 | N/A |
| 9/30/2017 | N/A | -6 | N/A | -5 | N/A |
| 6/30/2017 | N/A | -6 | N/A | -6 | N/A |
| 3/31/2017 | N/A | -8 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -8 | N/A | -10 | N/A |
| 9/30/2016 | N/A | -9 | N/A | -12 | N/A |
| 6/30/2016 | N/A | -3 | N/A | -13 | N/A |
| 3/31/2016 | N/A | 6 | N/A | -15 | N/A |
| 12/31/2015 | N/A | 6 | N/A | -16 | N/A |
| 9/30/2015 | N/A | 14 | N/A | -17 | N/A |
| 6/30/2015 | N/A | -21 | N/A | -16 | N/A |
| 3/31/2015 | N/A | -55 | N/A | -13 | N/A |
| 12/31/2014 | N/A | -46 | N/A | -9 | N/A |
| 9/30/2014 | N/A | -56 | N/A | -5 | N/A |
| 6/30/2014 | N/A | -28 | N/A | -3 | N/A |
| 3/31/2014 | N/A | -13 | N/A | -3 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che RLMD rimarrà non redditizia nei prossimi 3 anni.
Guadagni vs Mercato: Si prevede che RLMD rimarrà non redditizia nei prossimi 3 anni.
Guadagni ad alta crescita: Si prevede che RLMD rimarrà non redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che RLMD non avrà alcun fatturato il prossimo anno.
Ricavi ad alta crescita: Si prevede che RLMD non avrà alcun fatturato il prossimo anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di RLMD è previsto essere elevato tra 3 anni